Impact BioMedical Inc. (NYSE: IBO) Announces 3F™ US Patent Issue
Impact BioMedical Inc. (NYSE: IBO) has announced the issuance of U.S. Patent No. 11,985,973 for its 3F™ technology platform, titled 'Insect Repelling Composition'. This patent, along with the previously granted U.S. Patent No. 11,246,310, covers natural insect repellent compositions derived from plant constituents and fragrances. These patents will expire in February 2039 and April 2040, respectively.
The 3F™ technology inhibits insect olfactory receptors, effectively 'blinding' insects to human presence. Potential applications include mosquito repellents and additives for detergents, shampoos, or lotions. This innovation addresses the global issue of vector-borne diseases, which account for 17% of all infectious diseases worldwide according to the WHO.
IBO CEO Frank D. Heuszel stated that this patent issuance demonstrates the company's successful business model in delivering unique proprietary technology for unmet healthcare needs. IBO is now accelerating discussions with potential partners to bring 3F™ to market in the US and globally.
Impact BioMedical Inc. (NYSE: IBO) ha annunciato il rilascio del Brevetto USA N. 11.985.973 per la sua piattaforma tecnologica 3F™, intitolato 'Composizione Repellente per Insetti'. Questo brevetto, insieme al già concesso Brevetto USA N. 11.246.310, copre composizioni repellenti naturali per insetti derivate da costituenti vegetali e fragranze. Questi brevetti scadranno rispettivamente a Febbraio 2039 e Aprile 2040.
La tecnologia 3F™ inibisce i recettori olfattivi degli insetti, 'ciecando' di fatto gli insetti alla presenza umana. Le applicazioni potenziali includono repellenti per zanzare e additivi per detersivi, shampoo o lozioni. Questa innovazione affronta la questione globale delle malattie trasmesse da vettori, che rappresentano il 17% di tutte le malattie infettive a livello mondiale secondo l'OMS.
Il CEO di IBO, Frank D. Heuszel, ha dichiarato che il rilascio di questo brevetto dimostra il modello di business di successo dell'azienda nel fornire tecnologia proprietaria unica per soddisfare esigenze sanitarie non soddisfatte. IBO sta ora accelerando le discussioni con potenziali partner per portare il 3F™ sul mercato negli Stati Uniti e a livello globale.
Impact BioMedical Inc. (NYSE: IBO) ha anunciado la emisión del Patente de EE. UU. No. 11,985,973 para su plataforma tecnológica 3F™, titulada 'Composición Repelente de Insectos'. Esta patente, junto con la Patente de EE. UU. No. 11,246,310 previamente otorgada, cubre composiciones naturales repelentes de insectos derivadas de componentes vegetales y fragancias. Estas patentes caducarán en Febrero de 2039 y Abril de 2040, respectivamente.
La tecnología 3F™ inhibe los receptores olfativos de los insectos, 'cegando' efectivamente a los insectos a la presencia humana. Las aplicaciones potenciales incluyen repelentes de mosquitos y aditivos para detergentes, champús o lociones. Esta innovación aborda el problema global de las enfermedades transmitidas por vectores, que representan el 17% de todas las enfermedades infecciosas en todo el mundo según la OMS.
El CEO de IBO, Frank D. Heuszel, declaró que la emisión de esta patente demuestra el modelo de negocio exitoso de la empresa para ofrecer tecnología propietaria única para necesidades de salud no satisfechas. IBO está ahora acelerando las discusiones con posibles socios para llevar 3F™ al mercado en EE. UU. y globalmente.
Impact BioMedical Inc. (NYSE: IBO)는 '곤충 퇴치 조성물'이라는 제목의 3F™ 기술 플랫폼에 대해 미국 특허 제11,985,973호의 발급을 발표했습니다. 이 특허는 이전에 발급된 미국 특허 제11,246,310호와 함께 plant constituents와 향료에서 유래한 자연 곤충 퇴치 조성을 포괄합니다. 이들 특허는 각각 2039년 2월과 2040년 4월에 만료됩니다.
3F™ 기술은 곤충의 후각 수용체를 억제하여 인간의 존재를 '눈멀게' 합니다. 잠재적 응용 분야에는 모기 퇴치제 및 세제, 샴푸, 로션의 첨가제가 포함됩니다. 이 혁신은 WHO에 따르면 전 세계 모든 감염병의 17%를 차지하는 매개체 질병의 글로벌 문제를 해결합니다.
IBO의 CEO인 Frank D. Heuszel은 이번 특허 발급이 충족되지 않은 건강 관리 요구 사항에 대해 독특한 독점 기술을 제공하는 회사의 성공적인 비즈니스 모델을 보여준다고 밝혔습니다. IBO는 이제 3F™를 미국 및 전 세계 시장에 선보이기 위해 잠재적 파트너와의 논의를 가속화하고 있습니다.
Impact BioMedical Inc. (NYSE: IBO) a annoncé l'émission du Brevet américain n° 11.985.973 pour sa plateforme technologique 3F™, intitulée 'Composition répulsive pour insectes'. Ce brevet, conjointement avec le Brevet américain n° 11.246.310 précédemment accordé, couvre des compositions répulsives naturelles à base de constituants végétaux et de fragrances. Ces brevets expireront respectivement en février 2039 et avril 2040.
La technologie 3F™ inhibe les récepteurs olfactifs des insectes, les 'rendant aveugles' à la présence humaine. Les applications potentielles incluent les insecticides contre les moustiques et des additifs pour détergents, shampoings ou lotions. Cette innovation répond à la problématique mondiale des maladies transmises par des vecteurs, représentant 17 % de toutes les maladies infectieuses dans le monde selon l'OMS.
Le PDG d'IBO, Frank D. Heuszel, a déclaré que la délivrance de ce brevet démontre le succès du modèle commercial de l'entreprise en fournissant des technologies uniques et propriétaires pour des besoins de santé non satisfaits. IBO accélère maintenant les discussions avec des partenaires potentiels pour commercialiser le 3F™ aux États-Unis et à l'échelle mondiale.
Impact BioMedical Inc. (NYSE: IBO) hat die Erteilung des US-Patents Nr. 11.985.973 für seine 3F™-Technologieplattform angekündigt, die den Titel 'Insektenabwehr-Mischung' trägt. Dieses Patent, zusammen mit dem zuvor erteilten US-Patent Nr. 11.246.310, deckt natürliche Insektenabwehrmittel ab, die aus pflanzlichen Bestandteilen und Düften stammen. Diese Patente laufen jeweils im Februar 2039 und April 2040 ab.
Die 3F™-Technologie hemmt die olfaktorischen Rezeptoren von Insekten und macht sie sozusagen 'blind' für menschliche Präsenz. Potenzielle Anwendungen umfassen Mückenabwehrmittel sowie Zusatzstoffe für Reinigungsmittel, Shampoos oder Lotionen. Diese Innovation behandelt das globale Problem von durch Vektoren übertragenen Krankheiten, die laut der WHO 17% aller Infektionskrankheiten weltweit ausmachen.
Der CEO von IBO, Frank D. Heuszel, erklärte, dass die Erteilung dieses Patents das erfolgreiche Geschäftsmodell des Unternehmens zeigt, das einzigartige proprietäre Technologien für unerfüllte Gesundheitsbedürfnisse bereitstellt. IBO beschleunigt nun die Gespräche mit potenziellen Partnern, um 3F™ auf den Markt in den USA und international zu bringen.
- Issuance of new U.S. Patent No. 11,985,973 for 3F™ technology platform
- Extension of patent protection until February 2039 and April 2040
- Potential applications in insect repellents and personal care products
- Addressing a significant global health issue (vector-borne diseases)
- Accelerating discussions with potential partners for market entry
- None.
Insights
The issuance of U.S. Patent No. 11,985,973 for Impact BioMedical's 3F™ technology platform is a significant development. This patent, along with the previously granted U.S. Patent No. 11,246,310, strengthens IBO's intellectual property portfolio in the natural insect repellent space. The patents cover compositions derived from plant constituents and fragrances, potentially offering a novel approach to insect control.
Key points to consider:
- Patent expiration dates extend to 2039 and 2040, providing long-term market exclusivity
- Potential applications include human insect repellents and additives for personal care products
- Addresses a significant global health issue, with vector-borne diseases accounting for
17% of infectious diseases worldwide - Market potential is substantial, given the widespread need for effective, natural insect repellents
While this patent issuance is positive, investors should note that commercialization efforts are still in early stages. The company's focus on accelerating discussions with potential partners suggests a strategy to monetize this technology, which could lead to future revenue streams if successful. However, the timeline and potential financial impact remain uncertain at this stage.
The issuance of this patent positions Impact BioMedical favorably in the growing natural insect repellent market. Key market insights include:
- Increasing consumer preference for natural and plant-based products
- Rising awareness of vector-borne diseases, driving demand for effective repellents
- Potential for integration into multiple product categories (standalone repellents, personal care products)
- Global market expansion opportunities, particularly in regions with high incidence of insect-borne diseases
The company's strategy to pursue partnerships for market entry is prudent, potentially accelerating commercialization and reducing go-to-market costs. However, success will depend on factors such as product efficacy, safety profile and competitive pricing compared to existing solutions. The market for insect repellents is competitive, with established players and various synthetic options available. IBO's natural formulation could be a key differentiator, but market acceptance and regulatory approvals will be critical hurdles to overcome. Investors should monitor progress on partnership discussions and any upcoming efficacy or safety studies as indicators of potential market impact.
HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (“IBO”) is pleased to announce that the US Patent and Trademark Office has issued U.S. Patent No. 11,985,973 entitled “Insect Repelling Composition” developed within IBO’s 3F™ technology platform.
This is in addition to IBO’s prior granted U.S. Patent No. 11,246,310. Both patents include compositions and formulations of constituents found in plants and fragrances produced by plants, which, when applied as a natural insect repellent, have the potential to reduce insect landings and bites experienced in an outdoor environment. The terms of U.S. Patents 11,985,973 and 11,246,310 will expire in February 2039 and April 2040, respectively.
This expands Impact BioMedical’s 3F™ patent estate, which includes insect repellent compositions and anti-microbial applications in the United States and other countries. It also further demonstrates IBO’s commitment to discovering, developing, and patenting unique technologies to meet unmet needs in human healthcare.
These compositions and/or formulations inhibit the olfactory receptors either specifically or universally to “blind” the insect to human presence. Potential applications of the technology include use as a human insect (e.g., mosquito) repellent and/or as an addition to detergents, shampoos, or lotions to repel insect activity.
According to the World Health Organization, vector-borne diseases account for approximately
Upon notification of the patent issue, IBO CEO Frank D. Heuszel said, “This is another demonstration of success with our business model delivering new unique proprietary technology with the potential to address unmet needs in human healthcare. We are now accelerating discussions with potential partners to move 3F™ rapidly towards the market in the US and other countries worldwide.”
About Impact BioMedical, Inc.:
Impact BioMedical Inc. discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships.
Safe Harbor Disclosure:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date.
Media Contact:
Emily Martin
Email: emartin@impactbiomedinc.com
Investor Relations:
info@impactbiomedinc.com
FAQ
What is the new patent issued to Impact BioMedical Inc. (NYSE: IBO) for its 3F™ technology?
How long will Impact BioMedical's (NYSE: IBO) new 3F™ technology patents be valid?
What are the potential applications of Impact BioMedical's (NYSE: IBO) 3F™ technology?
How does Impact BioMedical's (NYSE: IBO) 3F™ technology work to repel insects?
